- Article
 
Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
- Christoph Wetz,
 - Julian Rogasch,
 - Philipp Genseke,
 - Imke Schatka,
 - Christian Furth,
 - Michael Kreissl,
 - Henning Jann,
 - Marino Venerito and
 - Holger Amthauer
 
Background: in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET), the mTOR inhibitor everolimus is associated with significant improvement in progression-free survival (PFS). This study evaluated the lesional asphericity (ASP) in p...

